BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2405493)

  • 1. Status of colony-stimulating factors in cancer and AIDS.
    Groopman JE
    Semin Oncol; 1990 Feb; 17(1 Suppl 1):31-7; discussion 38-41. PubMed ID: 2405493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of colony-stimulating factors.
    Groopman JE
    Semin Oncol; 1988 Dec; 15(6 Suppl 6):27-33. PubMed ID: 2462748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical applications of recombinant human colony-stimulating factors.
    Klingemann HG
    CMAJ; 1989 Jan; 140(2):137-42. PubMed ID: 2642725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical use of colony stimulating factors.
    Moore MA
    Annu Rev Immunol; 1991; 9():159-91. PubMed ID: 1910675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Vadhan-Raj S; Keating M; LeMaistre A; Hittelman WN; McCredie K; Trujillo JM; Broxmeyer HE; Henney C; Gutterman JU
    N Engl J Med; 1987 Dec; 317(25):1545-52. PubMed ID: 3500414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.
    Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
    J Clin Oncol; 1989 Feb; 7(2):159-67. PubMed ID: 2644395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and toxicity of the colony-stimulating factors.
    Schriber JR; Negrin RS
    Drug Saf; 1993 Jun; 8(6):457-68. PubMed ID: 7687134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic growth factors in cancer.
    Moore MA
    Cancer; 1990 Feb; 65(3 Suppl):836-44. PubMed ID: 2406005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer.
    Fan D; O'Brian CA; Ioannides CG; Clyne RK
    In Vivo; 1991; 5(6):571-7. PubMed ID: 1810441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status of the clinical application of hematopoietic growth factors in oncology].
    Karthaus M; Ganser A
    Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GM-CSF and G-CSF: cytokines in clinical application].
    Ruef C; Coleman DL
    Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of the myeloid growth factors.
    Glaspy JA; Golde DW
    Semin Hematol; 1989 Apr; 26(2 Suppl 2):14-7. PubMed ID: 2471274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations.
    Demetri GD; Antman KH
    Semin Oncol; 1992 Aug; 19(4):362-85. PubMed ID: 1509275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human recombinant derived IL-3 and GM-CSF in hematopoiesis of normal cynomolgus monkeys.
    Krumwieh D; Weinmann E; Seiler FR
    Behring Inst Mitt; 1988 Aug; (83):250-7. PubMed ID: 3071338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CSFs in preleukemia.
    Greenberg PL; Negrin R; Nagler A
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():121-6. PubMed ID: 1697191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
    Broxmeyer HE; Cooper S; Williams DE; Hangoc G; Gutterman JU; Vadhan-Raj S
    Exp Hematol; 1988 Aug; 16(7):594-602. PubMed ID: 3260558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
    Brandt SJ; Peters WP; Atwater SK; Kurtzberg J; Borowitz MJ; Jones RB; Shpall EJ; Bast RC; Gilbert CJ; Oette DH
    N Engl J Med; 1988 Apr; 318(14):869-76. PubMed ID: 3281007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.